1. Lead Researcher: Jennifer Soung, M.D.

2. Study Title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab

3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research study is to learn more about the use of Enbrel ® (etanercept) in people with psoriasis who have lost response to Humira ® (adalimumab).

4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Adults who have been diagnosed with psoriasis

5. Location (if other than UCIMC): University of California, Irvine, Dermatology Research, 1001 Hewitt Hall, Irvine, CA 92697

6. Time Commitment (e.g., three one-hour long visits in three weeks): This study includes 8 visits and takes about 7 hours over a period of approximately 30 weeks.

7. Anticipated Benefits (if any): Taking part in this study may or may not make your health better. While researchers hope that Enbrel ® (etanercept) will be better than the standard (usual) treatment, there is no proof of this yet.

8. Compensation (if any): You may be compensated up to $280.

9. Contact Name, UCI Department, Phone Number and E-mail: Brian Swasdibutra
UCI Dermatology Research
949-824-2319
bswasdib@uci.edu

Signature of Lead Researcher: ____________________________ Date: ___________